<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">AiM</journal-id><journal-title-group><journal-title>Advances in Microbiology</journal-title></journal-title-group><issn pub-type="epub">2165-3402</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/aim.2023.1312036</article-id><article-id pub-id-type="publisher-id">AiM-129986</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biomedical&amp;Life Sciences</subject></subj-group></article-categories><title-group><article-title>
 
 
  Antibiotics Resistance of Urogenital Mycoplasma in Sexually Active Women Attending Gynecologic Consultation in Douala (Cameroon)
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Jean</surname><given-names>Pierre Nda Mefo’o</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Rosa</surname><given-names>Fetue Notio</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Fulbert</surname><given-names>Mangala Nkwele</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Grace</surname><given-names>Dalle Ngondi</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Emmanuel</surname><given-names>Roddy Mengue</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Elodie</surname><given-names>Ngo Malabo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Charlotte</surname><given-names>Tchente Nguefack</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Cécile</surname><given-names>Okalla Ebongue</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Théophile</surname><given-names>Nana Njamen</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Laboratory of Clinical Biology, Douala General Hospital, Douala, Cameroon</addr-line></aff><aff id="aff4"><addr-line>Mother and Child Department, Douala General Hospital, Douala, Cameroon</addr-line></aff><aff id="aff2"><addr-line>Department of Biological Sciences, Faculty of Medicine and Pharmaceutical Sciences, The University of Douala, Douala, Cameroon</addr-line></aff><aff id="aff5"><addr-line>Department of Obstetrics and Gynecology, Faculty of Health Sciences, University of Buea, Buea, Cameroon</addr-line></aff><aff id="aff3"><addr-line>Department of Surgery and Specialties, Faculty of Medicine and Pharmaceutical Sciences, The University of Douala, Douala, Cameroon</addr-line></aff><pub-date pub-type="epub"><day>22</day><month>12</month><year>2023</year></pub-date><volume>13</volume><issue>12</issue><fpage>559</fpage><lpage>570</lpage><history><date date-type="received"><day>16,</day>	<month>October</month>	<year>2023</year></date><date date-type="rev-recd"><day>22,</day>	<month>December</month>	<year>2023</year>	</date><date date-type="accepted"><day>25,</day>	<month>December</month>	<year>2023</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  <b>Introduction:</b> Mycoplasmas are bacteria commonly found in the commensal flora of humans and can occasionally be pathogenic. The population and the geographical area determine their susceptibility to various antibiotics. 
  <b>Methodology:</b> We carried out a cross-sectional study from January to June 2022 at the Douala General Hospital. All women who were sexually active and willing to participate were included. Endo-cervical swabbing was used to collect the samples. Culture and antibiotic susceptibility testing were performed in a liquid medium using Mycoplasma-SystemPlus Gallery (Liofilchem). All samples that degraded urea (threshold &gt; 10
  <sup>3</sup> for 
  Ureaplasma urealyticum) and arginine (threshold &gt; 10
  <sup>4</sup> for 
  Mycoplasma hominis) were deemed positive. 
  <b>Results:</b> A total of 107 women with a median age of 33 &#177; 8.3 years and a predominance of 30-40 years (41.1%) were included. The frequency of mycoplasma infection was 73.8% with 34.1%, 11.4% and 54.4% for 
  Ureaplasma urealyticum, 
  Mycoplasma hominis and co-infection respectively. Resistance rates to Minocycline were low, 1.3% for 
  Ureaplasma urealyticum and 3.7% for co-infection; for Pefloxacin the resistance rates were 3.7% (
  Ureaplasma urealyticum, 
  Mycoplasma hominis) and 22.8% (co-infection). 
  Ureaplasma urealyticum had a resistance rate of 3.7% for Erythromycin, 1.3% for Clarithromycin and 5% for Azithromycin. There was no significant correlation between risk factors and infection. Vaginal cleansing and the development of resistance in mycoplasma infection were found to be significantly correlated (OR = 6.915 [1.52 - 31.55]; (p = 0.013)). 
  <b>Conclusion:</b> Minocycline was the most active antibiotic and 
  Ureaplasma urealyticum was the species with the lowest rate of resistance. Antibiotic resistance was more common in co-infected people than mono-infected. Antibiotic resistance was independently correlated with vaginal douching.
 
</p></abstract><kwd-group><kwd>Urogenital Mycoplasma</kwd><kwd> Sexually Active Women</kwd><kwd> Douala</kwd><kwd> Cameroon</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Urogenital mycoplasmas are bacteria that are commonly found in the commensal flora of humans and can occasionally be harmful [<xref ref-type="bibr" rid="scirp.129986-ref1">1</xref>] . These microorganisms are frequently linked to a number of diseases, including reproductive disorders, cervicitis, non-gonococcal urethritis, premature rupture of membranes during pregnancy, neonatal infections and bacterial vaginosis [<xref ref-type="bibr" rid="scirp.129986-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.129986-ref3">3</xref>] . Currently, urogenital infections have been linked to at least five different species of mycoplasma; the most common species are Mycoplasma hominis and Ureaplasma urealyticum, while the less common are M. genitalium, M. fermentans and M. penetrans [<xref ref-type="bibr" rid="scirp.129986-ref4">4</xref>] . Mycoplasma infections epidemiological data continue to differ depending on the study population and geographical area; for instance, genital swabs from men in China showed a prevalence of 43.7% genital mycoplasma, and 24.6% was recorded in Padua, Italy [<xref ref-type="bibr" rid="scirp.129986-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.129986-ref6">6</xref>] . Mycoplasma infection rates are still high in Sub-Saharan Africa [<xref ref-type="bibr" rid="scirp.129986-ref7">7</xref>] . The combined frequency of Mycoplasma hominis and Ureaplasma urealyticum in vaginal swabs was 7% in a 2009 study conducted in Burkina Faso [<xref ref-type="bibr" rid="scirp.129986-ref7">7</xref>] . In Benin, 35.1% of people tested positive for mycoplasma [<xref ref-type="bibr" rid="scirp.129986-ref8">8</xref>] . It was discovered that 71.4% of women living with Human Immunodeficiency Virus (HIV) in Cameroon also had mycoplasma infections [<xref ref-type="bibr" rid="scirp.129986-ref9">9</xref>] . Two comparable studies, one in Douala among sexually active women and the other one in Yaound&#233; among pregnant women, reported a prevalence of 65% and 38% respectively [<xref ref-type="bibr" rid="scirp.129986-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.129986-ref11">11</xref>] . Despite the existing therapeutic arsenal that includes antibiotics from the Cyclin, Macrolide-lincosamide and Fluoroquinolone families, it has been noted that Mycoplasma is developing acquired resistance to these widely used antibiotics [<xref ref-type="bibr" rid="scirp.129986-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.129986-ref13">13</xref>] . While Clarithromycin, Josamycin and Doxycycline remained active, a notable rate of resistance to Ciprofloxacin, Ofloxacin, Azithromycin and Erythromycin was observed in Italy and Switzerland [<xref ref-type="bibr" rid="scirp.129986-ref14">14</xref>] [<xref ref-type="bibr" rid="scirp.129986-ref15">15</xref>] . Josamycin showed good activity against all the species in C&#244;te d’Ivoire, including M. hominis and U. urealyticum, whereas Fluoroquinolones showed poor activity [<xref ref-type="bibr" rid="scirp.129986-ref2">2</xref>] . The degree of resistance differs from one country to another, based on treatment guidelines and even between populations [<xref ref-type="bibr" rid="scirp.129986-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.129986-ref13">13</xref>] . In genital swabs from HIV-positive women, the susceptibility to Fluoroquinolones declines with time (20% for ofloxacin and 18.3% for ciprofloxacin); the majority of Mycoplasma isolates are resistant to Erythromycin, Roxithromycin, Clindamycin, Ciprofloxacin and Clarithromycin in pregnant women [<xref ref-type="bibr" rid="scirp.129986-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.129986-ref10">10</xref>] .</p><p>The aim of this study was to determine the degree of antibiotic-resistant Mycoplasma in genital swabs from sexually active women attending the Douala General Hospital.</p></sec><sec id="s2"><title>2. Methodology</title><sec id="s2_1"><title>2.1. Type of Study, Location and Study Period</title><p>From January to June 2022, a cross-sectional study was carried out at the Douala General Hospital (DGH). Samples were collected in the Department of Gynecology and examined in the bacteriology unit of the Clinical Biology Laboratory.</p></sec><sec id="s2_2"><title>2.2. Study Population</title><p>These were sexually active women that visited the DGH for consultation in the Department of Gynecology and those seen at the Douala General Hospital laboratory.</p><p>After obtaining their informed consent, women who agreed to participate and who had not received any antibiotic therapy (aminoglycosides, macrolides, quinolones) for a period of at least one week were selected. Women who were menstruating, those who had had sex for less than 24 hours and/or who had taken a vaginal shower the morning of the sampling were not included. The Cochrane formula was used to determine the minimum participant size.</p></sec><sec id="s2_3"><title>2.3. Data Collection</title><p>Data were collected using a pre-tested individual survey form, including socio-demographics such as age, marital status and socio-professional category. Physiological criteria like pregnancy and menopause were assessed, as were clinical variables such as use of contraceptives, intimate gel and vaginal cleansing, pelvic pain, vaginal discharge and history of sexually transmitted infection.</p></sec><sec id="s2_4"><title>2.4. Sample Collection</title><p>An endo-cervical genital specimen was taken from each woman using a sterile swab.</p></sec><sec id="s2_5"><title>2.5. Seeding and Incubation of the Gallery</title><p>The colorimetric-based Mycoplasma System Plus<sup>TM</sup> (Liofilchem) gallery, for the detection, semi-quantitative counting, presumptive identification and antibiotic susceptibility test of Mycoplasma hominis and Ureaplasma urealyticum, was used according to the manufacturer’s recommendations. It also enabled the detection and presumptive identification of other microorganisms such as Trichomonas vaginalis and Candida spp.</p><p>After incubation at 36˚C &#177; 1˚C for 24 hours (and up to 48 hours in case of negativity on the first day) in an oven, Ureaplasma spp. counts were indicated by a color change from yellow to red in the corresponding wells (10<sup>3</sup>, 10<sup>4</sup> and ≥10<sup>5</sup>), as was Mycoplasma hominis (10<sup>4</sup> and ≥10<sup>5</sup>).</p><p>The presence of Trichomonas vaginalis and Candida spp. was determined microscopically (40&#215;) by examining culture fluid taken from the corresponding wells (presence of flagellated motile trophozoites for T. vaginalis and/or the presence of chlamydospores and hyphae for Candida spp).</p><p>Antibiotic susceptibility testing of urogenital mycoplasmas, based on 9 antibiotics (Tetracycline, Pefloxacin, Ofloxacin, Doxycycline, Erythromycin, Clarithromycin, Minocycline, Clindamycin, Azithromycin) was assessed by observing a color change from yellow to red in the corresponding wells.</p></sec><sec id="s2_6"><title>2.6. Statistical Analysis</title><p>The data were analyzed using Epi Info software version 7.2.2.1. The Chi<sup>2</sup> test was used for comparison of categorical variables and the Student T-test for continuous quantitative variables (mean, median). Values of p-value &lt; 0.05 were considered significant and the strength of association was delivered as an odds ratio with 95% CI.</p></sec></sec><sec id="s3"><title>3. Results</title><p>A total of 187 women were targeted in the gynecology and laboratory departments and 107 were recruited according to inclusion criteria.</p><p>Age</p><p>The median age of the study population was 33 &#177; 8.3 years with a minimum of 21 years and a maximum of 59 years. The most represented age group was 30-40 years, i.e. 41.1%.</p><p>Socio-professional category</p><p>The majority of the study population (63.6%) was salaried. Students represented 22.4% of the participants.</p><p>Marital status</p><p>According to marital status, the most represented class was married women (52.3%).</p><p>Region of origin</p><p>An analysis by region of origin shows that in this sample of patients, the most represented region was the West (35.5%).</p><p>Number of sexual partners</p><p>Of the 107 women we interviewed, 85% had a single sexual partner, 11.2% had two, 1.9% had 3, and 1.9% had 4 partners.</p><p>Physiological condition</p><p>Analysis of the women’s condition showed that 18.7% were pregnant and 6.5% were already menopausal.</p><p>Clinical and Para clinical features</p><p>Reason for consultation</p><p>Some women presented several reasons for consultation. The most common reason was routine or premarital check-ups (29.9%) and the prenatal consultation of pregnant women represented 17.8%.</p><p>History of sexually transmitted infections (STIs)</p><p>The results showed that 39.3% of women had already contracted an STI such as chlamydia, herpes or mycoplasma.</p><p>The percentage of women using no form of contraception method was higher (82.2%), compared to those using intrauterine devices (8.4%), condoms (6.5%), orals (2.5) and then injectable (0.9%) (<xref ref-type="table" rid="table1">Table 1</xref>).</p><p>Frequency of mycoplasma infection</p><p>The proportion of women with urogenital mycoplasma infection was 73.8%.</p><p>Candida albicans was found in 31.7% of cases, none of the women tested were carriers of Trichomonas vaginalis and 15.9% of the study population had no infections (mycoplasma, Candida spp, Trichomonas vaginalis).</p><p>The age group most infected with Ureaplasma urealyticum and co-infection was 30 to 40, with 37.5% and 56.3% respectively.</p><p>Among women who tested positive for urogenital mycoplasma infections, those with co-infection (Ureaplasma urealyticum and Mycoplasma hominis) were in the majority, accounting for 54.4% of cases (<xref ref-type="table" rid="table2">Table 2</xref>).</p><p>Resistance profile of urogenital mycoplasma to the antibiotics tested</p><p>Minocycline was the most active antibiotic for Mycoplasma hominis (resistance rate 0%). There was a high level of resistance to Erythromycin, Clarithromycin, Azithromycin and Tetracycline - 100% for the first two, 88.8% and 77.8% respectively.</p><p>Clarithromycin was the most active antibiotic for Ureaplasma urealyticum (resistance rate 3.7%). A high rate of resistance to clindamycin (100%), followed by tetracycline (33.3%), was observed for this same species.</p><p>Based on the results of the antibiotic resistance profile, Minocycline was the most active antibiotic for cases of co-infection (resistance rate 9.3%).</p><p>The rate of resistance to erythromycin was 100% in cases of co-infection and Mycoplasma hominis infection; 100% and 97.7% for clindamycin in Ureaplasma urealyticum infection and co-infections respectively (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><p>The most active antibiotic for all colonizing species was Minocycline.</p><p>Factors associated with mycoplasma infection</p><p>There was no significant association between factors such as age, socio-professional categories, marital status, hormonal status, non-use of contraceptives, number of sexual partners and Mycoplasma infection (<xref ref-type="table" rid="table1">Table 1</xref>).</p><p>Factors associated with Clarithromycin antibiotic resistance</p><p>In univariate analysis, four parameters were independently associated with Clarithromycin resistance; such as Pelvic pain, Use of intimate gel resistance, inflamed cervix and vaginal cleansing. However, in multivariate analysis, only Pelvic pain can be associated with this resistance with OR = 3.054 [1.311 - 7.1186], p = 0.010 (<xref ref-type="table" rid="table3">Table 3</xref>).</p><disp-formula id="scirp.129986-formula1"><graphic  xlink:href="//html.scirp.org/file/1-2271999x4.png?20240112161327294"  xlink:type="simple"/></disp-formula><p>Resistance of the various strains to the antibiotics tested. TET, Tetracycline; PEF, Cefepime; OFX, Ofloxacin; DOX, Doxicycline; ERY, Erythromycin; CLA, Clarithomycin; MN, Minocycline; CD, Clindamycin; AZM, Azitromycin.</p><p><xref ref-type="fig" rid="fig1">Figure 1</xref>. Antibiotic resistance profile of different strains (N = 79).</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Factors associated with Mycoplasma infection</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"   rowspan="2"  >Variables</th><th align="center" valign="middle"  colspan="2"  >Culture N = 107 [n (%)]</th><th align="center" valign="middle"  rowspan="2"  >Total n (%)</th><th align="center" valign="middle"  rowspan="2"  >p-value</th><th align="center" valign="middle"  rowspan="2"  >Odds ratio</th><th align="center" valign="middle"  rowspan="2"  >95% CIS2</th></tr></thead><tr><td align="center" valign="middle" >Negative 28 (26.2)</td><td align="center" valign="middle" >Positive 79 (73.8)</td></tr><tr><td align="center" valign="middle"  rowspan="4"  >Age (Years) Mean = 33 &#177; 8.3 Min-max (21 - 59)</td><td align="center" valign="middle" >[20 - 30[</td><td align="center" valign="middle" >10 (35.7)</td><td align="center" valign="middle" >25 (31.6)</td><td align="center" valign="middle" >35 (32.7)</td><td align="center" valign="middle"  rowspan="4"  >0.302</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >[30 - 40[</td><td align="center" valign="middle" >12 (42.9)</td><td align="center" valign="middle" >32 (40.5)</td><td align="center" valign="middle" >44 (41.1)</td><td align="center" valign="middle" >1.190</td><td align="center" valign="middle" >0.310 - 4.570</td></tr><tr><td align="center" valign="middle" >[40 - 50[</td><td align="center" valign="middle" >6 (21.4)</td><td align="center" valign="middle" >15 (19.0)</td><td align="center" valign="middle" >21 (19.6)</td><td align="center" valign="middle" >1.500</td><td align="center" valign="middle" >0,000 - 1</td></tr><tr><td align="center" valign="middle" >[50 - 60[</td><td align="center" valign="middle" >0 (0.00)</td><td align="center" valign="middle" >7 (8.9)</td><td align="center" valign="middle" >7 (6.5)</td><td align="center" valign="middle" >0.174</td><td align="center" valign="middle" >0.020 - 1.491</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >Socio-professional category</td><td align="center" valign="middle" >Student</td><td align="center" valign="middle" >8 (28.6)</td><td align="center" valign="middle" >16 (20.3)</td><td align="center" valign="middle" >24 (22.4)</td><td align="center" valign="middle"  rowspan="3"  >0.801</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Employee</td><td align="center" valign="middle" >16 (57.1)</td><td align="center" valign="middle" >52 (65.8)</td><td align="center" valign="middle" >68 (63.6)</td><td align="center" valign="middle" >1.454</td><td align="center" valign="middle" >0.329 - 6.416</td></tr><tr><td align="center" valign="middle" >Unemployed</td><td align="center" valign="middle" >4 (14.3)</td><td align="center" valign="middle" >11 (13.9)</td><td align="center" valign="middle" >15 (14.0)</td><td align="center" valign="middle" >0.950</td><td align="center" valign="middle" >0,139 - 6,500</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >Marital status</td><td align="center" valign="middle" >Single</td><td align="center" valign="middle" >9 (32.1)</td><td align="center" valign="middle" >23 (29.1)</td><td align="center" valign="middle" >32 (29.9)</td><td align="center" valign="middle"  rowspan="3"  >0.695</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Cohabitation</td><td align="center" valign="middle" >4 (14.3)</td><td align="center" valign="middle" >15 (19.0)</td><td align="center" valign="middle" >19 (17.8)</td><td align="center" valign="middle" >1.637</td><td align="center" valign="middle" >0.224 - 11.991</td></tr><tr><td align="center" valign="middle" >Married</td><td align="center" valign="middle" >15 (53.6)</td><td align="center" valign="middle" >41 (51.9)</td><td align="center" valign="middle" >56 (52.3)</td><td align="center" valign="middle" >0.808</td><td align="center" valign="middle" >0.194 - 3.374</td></tr><tr><td align="center" valign="middle"  rowspan="4"  >Number of sexual partners</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >25 (89.3)</td><td align="center" valign="middle" >66 (83.5)</td><td align="center" valign="middle" >91 (85.0)</td><td align="center" valign="middle"  rowspan="4"  >0.495</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1 (3.6)</td><td align="center" valign="middle" >11 (13.9)</td><td align="center" valign="middle" >12 (11.2)</td><td align="center" valign="middle" >9.504</td><td align="center" valign="middle" >0.544 - 16.109</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1 (3.6)</td><td align="center" valign="middle" >1 (1.3)</td><td align="center" valign="middle" >2 (1.9)</td><td align="center" valign="middle" >1.649</td><td align="center" valign="middle" >0.037 - 73.054</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >1 (3.6)</td><td align="center" valign="middle" >1 (1.3)</td><td align="center" valign="middle" >2 (1.9)</td><td align="center" valign="middle" >0.950</td><td align="center" valign="middle" >0.025 - 36.636</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Physiological condition</td><td align="center" valign="middle" >Normal</td><td align="center" valign="middle" >20 (71.4)</td><td align="center" valign="middle" >60 (75.9)</td><td align="center" valign="middle" >80 (74.8)</td><td align="center" valign="middle"  rowspan="2"  >0.092</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Pregnant</td><td align="center" valign="middle" >7 (25.0)</td><td align="center" valign="middle" >13 (16.5)</td><td align="center" valign="middle" >20 (18.7)</td><td align="center" valign="middle" >0.474</td><td align="center" valign="middle" >0.136 - 1.660</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Menopausal</td><td align="center" valign="middle" >1 (3.6)</td><td align="center" valign="middle" >6 (7.6)</td><td align="center" valign="middle" >7 (6.5)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >11.728</td><td align="center" valign="middle" >0.716 - 192.049</td></tr><tr><td align="center" valign="middle"  rowspan="5"  >Contraception</td><td align="center" valign="middle" >No</td><td align="center" valign="middle" >22 (78.6)</td><td align="center" valign="middle" >66 (83.5)</td><td align="center" valign="middle" >88 (82.2)</td><td align="center" valign="middle"  rowspan="5"  >0.329</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Injectable</td><td align="center" valign="middle" >1 (3.6)</td><td align="center" valign="middle" >0 (0.0)</td><td align="center" valign="middle" >1 (0.9)</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >000</td></tr><tr><td align="center" valign="middle" >Orals</td><td align="center" valign="middle" >0 (0.0)</td><td align="center" valign="middle" >2 (2.5)</td><td align="center" valign="middle" >2 (1.9)</td><td align="center" valign="middle" >577</td><td align="center" valign="middle" >000</td></tr><tr><td align="center" valign="middle" >IUD</td><td align="center" valign="middle" >1 (3.6)</td><td align="center" valign="middle" >8 (10.1)</td><td align="center" valign="middle" >9 (8.4)</td><td align="center" valign="middle" >2.414</td><td align="center" valign="middle" >0.190 - 30.678</td></tr><tr><td align="center" valign="middle" >Condoms</td><td align="center" valign="middle" >4 (14.3)</td><td align="center" valign="middle" >3 (3.8)</td><td align="center" valign="middle" >7 (6.5)</td><td align="center" valign="middle" >0.077</td><td align="center" valign="middle" >0.006 - 1.008</td></tr></tbody></table></table-wrap><p>IUD = Intra Uterine Device.</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Frequency of pathogens in cultures and microscopy</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"   rowspan="2"  >Pathogens</th><th align="center" valign="middle"  colspan="2"  >Frequency</th></tr></thead><tr><td align="center" valign="middle" >n</td><td align="center" valign="middle" >%</td></tr><tr><td align="center" valign="middle"  rowspan="4"  >Mycoplasma</td><td align="center" valign="middle" >Ureplasma urealyticum</td><td align="center" valign="middle" >27</td><td align="center" valign="middle" >25.2</td></tr><tr><td align="center" valign="middle" >Mycoplasma hominis</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >8.4</td></tr><tr><td align="center" valign="middle" >U. urealyticum + M. hominis</td><td align="center" valign="middle" >43</td><td align="center" valign="middle" >40.2</td></tr><tr><td align="center" valign="middle" >Absence</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >26.2</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Total 1</td><td align="center" valign="middle" >107</td><td align="center" valign="middle" >100</td></tr><tr><td align="center" valign="middle"  rowspan="4"  >Parasite/Fungi</td><td align="center" valign="middle" >Trichomonas vaginalis</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >Candida albicans</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >10.3</td></tr><tr><td align="center" valign="middle" >C. albicans + Uu/Mh</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >21.5</td></tr><tr><td align="center" valign="middle" >None</td><td align="center" valign="middle" >73</td><td align="center" valign="middle" >68.2</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Total 2</td><td align="center" valign="middle" >107</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Factors associated with resistance to clarithromycin</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"   rowspan="2"  >Variables</th><th align="center" valign="middle"  colspan="2"  >Resistance N = 107 n (%)</th><th align="center" valign="middle"  rowspan="2"  >Total n (%)</th><th align="center" valign="middle"  rowspan="2"  >p-value</th><th align="center" valign="middle"  rowspan="2"  >Odds ratio</th><th align="center" valign="middle"  rowspan="2"  >95% CIS2</th></tr></thead><tr><td align="center" valign="middle" >No 63 (58.9)</td><td align="center" valign="middle" >Yes 44 (41.1)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Pelvic pain</td><td align="center" valign="middle" >No</td><td align="center" valign="middle" >47 (69.1)</td><td align="center" valign="middle" >21 (30.9)</td><td align="center" valign="middle" >68 (63.6)</td><td align="center" valign="middle"  rowspan="2"  >0. 010</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >16 (41.0)</td><td align="center" valign="middle" >23 (59.0)</td><td align="center" valign="middle" >39 (36.4)</td><td align="center" valign="middle" >3.054</td><td align="center" valign="middle" >1.311 - 7.118</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Use of intimate gel</td><td align="center" valign="middle" >No</td><td align="center" valign="middle" >52 (61.9)</td><td align="center" valign="middle" >32 (38.1)</td><td align="center" valign="middle" >84 (78.5)</td><td align="center" valign="middle"  rowspan="2"  >0.490</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >11 (47.8)</td><td align="center" valign="middle" >12 (52.2)</td><td align="center" valign="middle" >23 (21.5)</td><td align="center" valign="middle" >1.433</td><td align="center" valign="middle" >0.515 - 3.985</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Cervix aspect</td><td align="center" valign="middle" >Normal</td><td align="center" valign="middle" >14 (50.0)</td><td align="center" valign="middle" >14 (50.0)</td><td align="center" valign="middle" >79 (73.8)</td><td align="center" valign="middle"  rowspan="2"  >0. 349</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Inflammation</td><td align="center" valign="middle" >49 (62.0)</td><td align="center" valign="middle" >30 (38.0)</td><td align="center" valign="middle" >28 (26.2)</td><td align="center" valign="middle" >1.562</td><td align="center" valign="middle" >0.614 - 3.971</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Deep vaginal cleansing</td><td align="center" valign="middle" >No</td><td align="center" valign="middle" >52 (65.8)</td><td align="center" valign="middle" >27 (34.2)</td><td align="center" valign="middle" >79 (73.8)</td><td align="center" valign="middle"  rowspan="2"  >0.061</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >11 (39.3)</td><td align="center" valign="middle" >17 (60.7)</td><td align="center" valign="middle" >28 (26.2)</td><td align="center" valign="middle" >2.485</td><td align="center" valign="middle" >0.958 - 6.443</td></tr></tbody></table></table-wrap></sec><sec id="s4"><title>4. Discussion</title><p>The study population consisted of 107 women aged between 21 and 59 years. The age group with the highest rate of Ureaplasma urealyticum infection and co-infection was the 20 - 30 age group, with 56% and 56.4% respectively. There is a similarity with the results of work carried out in Mali by Guindo et al. in 2022, who showed that the most infected patients belonged to the 16 to 35 age group (45.2%) [<xref ref-type="bibr" rid="scirp.129986-ref16">16</xref>] .</p><p>Half of the study population was represented by married women (50%), followed by single women (31%), the majority of whom were salaried employees (63%). These results differ from those of Tebeu et al. found in a study carried out at the Yaound&#233; Gyneco-Obstetric and Pediatric Hospital in 2020, where the majority of women were students (24.8%) [<xref ref-type="bibr" rid="scirp.129986-ref17">17</xref>] .</p><p>Microbiological analyses showed that, in terms of physiological status, the frequency of mycoplasma infections was highest in post-menopausal women (85.7%), followed by non-pregnant women (75%).</p><p>The prevalence of mycoplasma infection was 73.8%, higher than those obtained by Longdoh et al. in 2011 in Yaound&#233;, Cameroon, Ndjamena, Chad, and Leli et al. in Italy (65%, 27% and 24.6% respectively) [<xref ref-type="bibr" rid="scirp.129986-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.129986-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.129986-ref18">18</xref>] . This difference can be explained by the fact that mycoplasma infections remain variable depending on the study population and geographical area [<xref ref-type="bibr" rid="scirp.129986-ref5">5</xref>] .</p><p>The most infected age group corresponds to that in which women are more sexually active.</p><p>The rates of colonization by Ureaplasma urealyticum, Mycoplasma hominis and co-infection in the study population were 25%, 9% and 39% respectively. In contrast, Bolti et al. found in 2022 that U. urealyticum was predominant, with an identification rate of 74% versus 21.7% for M. hominis; similarly, U. urealyticum/M. hominis co-infection was superior to M. hominis mono-infection [<xref ref-type="bibr" rid="scirp.129986-ref18">18</xref>] .</p><p>Trichomonas vaginalis, which we did not find in our series, could also be detected. The T. vaginalis/Mycoplasma grouping is an example of a combination of microorganisms of low virulence, which, together, are capable of producing potentially aggressive diseases [<xref ref-type="bibr" rid="scirp.129986-ref19">19</xref>] [<xref ref-type="bibr" rid="scirp.129986-ref20">20</xref>] . The symbiosis between T. vaginalis and M. hominis represents the first reported and unique case of association between two obligate parasitic organisms of man, capable of producing infections in the same anatomical site and causing independent diseases [<xref ref-type="bibr" rid="scirp.129986-ref19">19</xref>] . Mycoplasma hominis can influence the pathogenicity of T. vaginalis, suggesting a role for symbiosis in the variability of signs and symptoms observed during trichomoniasis [<xref ref-type="bibr" rid="scirp.129986-ref20">20</xref>] .</p><p>Ureaplasma urealyticum strains were highly sensitive to macrolides: 88%, 96% and 72% respectively for erythromycin, clarithromycin and azithromycin. In contrast, strains of Mycoplasma hominis were multi-resistant to the same family of antibiotics (i.e. 0% sensitivity to each). Co-infections also showed low levels of sensitivity to the macrolides tested. Ureaplasma urealyticum was totally resistant to Clindamycin. However, there is a discrepancy with the study carried out in 2019 by Kouassi et al. who found that 81.5%, 33.3% and 22.2% of M. hominis strains were sensitive to azithromycin, clarithromycin and erythromycin respectively [<xref ref-type="bibr" rid="scirp.129986-ref2">2</xref>] .</p><p>Minocycline was the most active molecule whatever the germ considered, and even in co-infection, with sensitivities of 92%, 100% and 92.3% respectively for U. urealyticum, M. hominis and co-infection. The other 2 cyclins remained highly effective against U.urealyticum, with 68% of strains sensitive to tetracycline and 80% to doxycycline. However, activity against Mycoplasma hominis and the 2 co-infected germs was lower (22.2% and 22.2%) and (17.9% and 66.7%) respectively. These results are similar to those of Zhu et al. in 2016 in China, where cyclins were the molecules that showed the best activity on all mycoplasmas compared with other antibiotic families [<xref ref-type="bibr" rid="scirp.129986-ref6">6</xref>] .</p><p>The level of cyclin resistance was highest with M. hominis, at 77.8%, 33.3% and 0% respectively for tetracycline, doxycycline and minocycline; for U. urealyticum, it was 32% for tetracycline, 16% for doxycycline and 4% for minocycline. This level of resistance is higher than those obtained in Dakar by Diop-N’diaye et al. in 2014 with rates that varied between 5% and 14% [<xref ref-type="bibr" rid="scirp.129986-ref21">21</xref>] . Our results also diverge from those obtained in Burkina Faso by Karou et al. and in Cuba by Diaz et al. with tetracycline and doxycycline resistance rates of 20% and 25% respectively for U. urealyticum and 40% and 35% for M. hominis [<xref ref-type="bibr" rid="scirp.129986-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.129986-ref22">22</xref>] . The Fluoroquinolone family was the least resistant, although these rates remain high. However, these differences could be explained by the recurrent practice of self-medication in our countries and by the different infection management policies in place [<xref ref-type="bibr" rid="scirp.129986-ref23">23</xref>] .</p><p>Age, socio-professional and marital status, physiological state, non-use of contraceptives and number of sexual partners, were factors associated with mycoplasma infection, but were not significant. Similarly, Zhang et al. showed in their study that there was no association between mycoplasma infection and marital status, occupation, smoking, alcoholism, age, pregnancy and menopausal status [<xref ref-type="bibr" rid="scirp.129986-ref24">24</xref>] .</p><p>Vaginal cleansing is a factor significantly associated with the resistance of urogenital mycoplasmas to antibiotics. This could be explained by the fact that vaginal cleansing may be responsible for an imbalance in vaginal flora, thus promoting mycoplasma colonization of the genital tract [<xref ref-type="bibr" rid="scirp.129986-ref25">25</xref>] .</p></sec><sec id="s5"><title>5. Conclusion</title><p>The study showed that, of the species isolated, Ureaplasma urealyticum had good sensitivity to most macrolides, cyclins and quinolones Mycoplasma hominis and co-infections were multi-resistant to all these antibiotics except minocycline. It is therefore important to study the sensitivity of each mycoplasma species to antibiotics in cases of co-infection. Vaginal douche is a risk factor for vaginal infection.</p></sec><sec id="s6"><title>Study Limits</title><p>The size of the sample and the fact that this phenomenon was studied in a single structure mean that the conclusions of this work cannot be generalized.</p></sec><sec id="s7"><title>Acknowledgements</title><p>We would like to express our gratitude to all the women who agreed to take part in this study.</p></sec><sec id="s8"><title>Author Contributions</title><p>JPNM, COE and CTN coordinated the study; JPNM, RFN, FMN and COE drafted the manuscript; RFN, ERM and GDN collected the data, performed the laboratory analyses and interpreted the results. JPNM and TNJ participated in the study design. COE, ENM and ERM carried out the statistical analysis. All authors read and approved the final manuscript.</p></sec><sec id="s9"><title>Ethics</title><p>The study was conducted in accordance with the ethical guidelines for research in Cameroon. We obtained research authorizations from the Director of Douala General Hospital, and ethical approval from the Institutional Human Health Research Ethics Committee of the University of Douala (N˚ 3010 CEI-UDo/04/ 2022/M).</p></sec><sec id="s10"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s11"><title>Cite this paper</title><p>Nda Mefo’o, J.P., Notio, R.F., Nkwele, F.M., Ngondi, G.D., Mengue, E.R., Malabo, E.N., Nguefack, C.T., Ebongue, C.O. and Njamen, T.N. (2023) Antibiotics Resistance of Urogenital Mycoplasma in Sexually Active Women Attending Gynecologic Consultation in Douala (Cameroon). Advances in Microbiology, 13, 559-570. https://doi.org/10.4236/aim.2023.1312036</p></sec></body><back><ref-list><title>References</title><ref id="scirp.129986-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Andrzejczak-Grz&amp;aogon;dko, S. and Doli&amp;nacute;ska, I. (2019) Detection of Urogenital Mycoplasmas in Clinical Samples. Postepy Biochemii, 65, 299-305.</mixed-citation></ref><ref id="scirp.129986-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Kouassi-Agbessi, T.B., Cablan, A.M., Krizo, A.G., Zinzendorf, N.Y. and Amin, C.N.C. (2019) Study of Antibiotic Susceptibility of Mycoplasmas Isolated from Semen in Abidjan. International Journal of Biological and Chemical Sciences, 13, 1558-1564. https://doi.org/10.4314/ijbcs.v13i3.28</mixed-citation></ref><ref id="scirp.129986-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Lis, R., Rowhani-Rahbar, A. and Manhart, L.E. (2015) Mycoplasma Genitalium Infection and Female Reproductive Tract Disease: A Meta-Analysis. Clinical Infectious Diseases, 61, 418-426. https://doi.org/10.1093/cid/civ312</mixed-citation></ref><ref id="scirp.129986-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Jensen, J.S., Cusini, S., Gomberg, M., Moi, H., Wilson, J. and Unemo M. (2022) 2021 European Guideline on the Management of Mycoplasma genitalium Infections. Journal of the European Academy of Dermatology and Venereology, 36, 641-650. https://doi.org/10.1111/jdv.17972</mixed-citation></ref><ref id="scirp.129986-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Leli, C., Mencacci, A., Bombaci, J.C., D’Al&amp;ograve;, F., Farinelli, S., Vitali, M. and Bistoni, F. (2012) Prevalence and Antimicrobial Susceptibility of Ureaplasma urealyticum and Mycoplasma hominis in a Population of Italian and Immigrant Outpatients. Le Infezioni in Medicina, 20, 82-87.</mixed-citation></ref><ref id="scirp.129986-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Zhu, X., Li, M., Cao, H., Yang, X. and Zhang, C. (2016) Epidemiology of Ureaplasma urealyticum and Mycoplasma hominis in the Semen of Male Outpatients with Reproductive Disorders. Experimental and Therapeutic Medicine, 12, 1165-1170. https://doi.org/10.3892/etm.2016.3409</mixed-citation></ref><ref id="scirp.129986-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Karou, S.D., Djigma, F., Sagna, T., Nadembega, C., Zeba, M., Kabre, A. and Simpore, J. (2012) Antimicrobial Resistance of Abnormal Vaginal Discharges Microorganisms in Ouagadougou, Burkina Faso. Asian Pacific Journal of Tropical Biomedicine, 2, 294-297. https://doi.org/10.1016/S2221-1691(12)60025-2</mixed-citation></ref><ref id="scirp.129986-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Gandji, S., Bankol&amp;eacute;, H.S., Dougnon, T.V., Da Silva, J., Zannou, C. and Biaou, O. (2013) Occurrence of Tubal Obstructions in Women in Cotonou (Benin): Role of Bacteria. International Journal of Biological and Chemical Sciences, 7, 1338-1343. https://doi.org/10.4314/ijbcs.v7i3.39</mixed-citation></ref><ref id="scirp.129986-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Gonsu, H.K. (2014) Prevalence of Mycoplasma hominis and Ureaplasma urealyticum among Women Infected with HIV in Yaound&amp;eacute;-Cameroon. International Journal of Infectious Diseases, 21, 333. https://doi.org/10.1016/j.ijid.2014.03.1108</mixed-citation></ref><ref id="scirp.129986-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Longdoh, N.A., Gregory, H.E.E., Djeumako, W.A., Nguedia, A.J.C., Francois-Xavier, M.K. and Tebit, K.E. (2018) The Occurrence and Antimicrobial Susceptibility Patterns of Mycoplasma hominis and Ureaplasma urealyticum in Pregnant Women in Three District Hospitals in Douala, Cameroon. Journal of Advances in Medicine and Medical Research, 27, 1-11. https://doi.org/10.9734/JAMMR/2018/43356</mixed-citation></ref><ref id="scirp.129986-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Njunda, A.L., Nsagha, D.S., Assob, J.C., Palle, J.N., Kamga, H.L., Nde, P.F. and Weledji, P.E. (2011) Genital Mycoplasmas in Women Attending the Yaoundé University Teaching Hospital in Cameroon. Journal of Public Health in Africa, 2, e16.</mixed-citation></ref><ref id="scirp.129986-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Waites, K.B., Duffy, L.B., B&amp;eacute;b&amp;eacute;ar, C.M., Matlow, A., Talkington, D.F., Kenny, G.E. and Brown, S.D. (2012) Standardized Methods and Quality Control Limits for Agar and Broth Microdilution Susceptibility Testing of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum. Journal of Clinical Microbiology, 50, 3542-3547. https://doi.org/10.1128/JCM.01439-12</mixed-citation></ref><ref id="scirp.129986-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Mihai, M., Valentin, N., Bogdan, D., Carmen, C.M., Coralia, B. and Demetra, S. (2011) Antibiotic Susceptibility Profiles of Mycoplasma hominis and Ureaplasma urealyticum Isolated during a Population-Based Study Concerning Women Infertility in Northeast Romania. Brazilian Journal of Microbiology, 42, 256-260. https://doi.org/10.1590/S1517-83822011000100032</mixed-citation></ref><ref id="scirp.129986-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Bartolini, A., Scapaticci, M., Akkouche, W., Boldrin, C. and Rossi, L. (2017) Prevalence and Antimicrobial Susceptibility of Genital Mycoplasmas Detected by Mycoplasma IST 2 from Urogenital Samples in Padua, Italy, Between January 2014 and December 2015. Microbiologia Medica, 32, Article No. 6503. https://doi.org/10.4081/mm.2017.6503</mixed-citation></ref><ref id="scirp.129986-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Schneider, S.C., Tinguely, R., Droz, S., Hilty, M., Donà, V., Bodmer, T. and Endimiani, A. (2015) Antibiotic Susceptibility and Sequence Type Distribution of Ureaplasma Species Isolated from Genital Samples in Switzerland. Antimicrobial Agents and Chemotherapy, 59, 6026-6031. https://doi.org/10.1128/AAC.00895-15</mixed-citation></ref><ref id="scirp.129986-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Y&amp;imath;ld&amp;imath;r&amp;imath;m, R., Vural, G. and Koo&amp;gbreve;lu, E. (2020) Effect of Vaginal Douching on Vaginal Flora and Genital Infection. Journal of the Turkish German Gynecological Association, 21, 29-34. https://doi.org/10.4274/jtgga.galenos.2019.2018.0133</mixed-citation></ref><ref id="scirp.129986-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, W., Li, L., Zhang, X., Fang, H., Chen, H. and Rong, C. (2021) Infection Prevalence and Antibiotic Resistance Levels in Ureaplasma urealyticum and Mycoplasma hominis in Gynecological Outpatients of a Tertiary Hospital in China from 2015 to 2018. Canadian Journal of Infectious Diseases and Medical Microbiology, 2021, Article ID: 8842267. https://doi.org/10.1155/2021/8842267</mixed-citation></ref><ref id="scirp.129986-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Yeika, E.V., Ingelbeen, B., Kemah, B.L., Wirsiy, F.S., Fomengia, J.N. and Van der Sande, M.A. (2021) Comparative Assessment of the Prevalence, Practices and Factors Associated with Self-Medication with Antibiotics in Africa. Tropical Medicine &amp; International Health, 26, 862-881. https://doi.org/10.1111/tmi.13600</mixed-citation></ref><ref id="scirp.129986-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">D&amp;iacute;az, L., Cabrera, L.E., Fern&amp;aacute;ndez, T., Ib&amp;aacute;&amp;ntilde;ez, I., Torres, Y., Obreg&amp;oacute;n, Y. and Rivero, Y. (2013) Frequency and Antimicrobial Sensitivity of Ureaplasma urealyticum and Mycoplasma hominis in Patients with Vaginal Discharge. MEDICC Review, 15, 45-47. https://doi.org/10.37757/MR2013V15.N4.11</mixed-citation></ref><ref id="scirp.129986-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Diop-N’diaye, H., Gueye, M., Camara, M., Gueye, S.B., Ba-Diallo, A., Karam, F. and Gaye-Diallo, A. (2014) Antibiotic Susceptibility of Mycoplasma hominis and Ureaplasma urealyticum Isolated from the Genital Tract of Women in Dakar. Dakar Medical, 59, 177-184.</mixed-citation></ref><ref id="scirp.129986-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Wen, A., Srinivasan, U., Goldberg, D., Owen, J., Marrs, C.F., Misra, D., Wing, D.A., Ponnalur, S., Miles-Jay, A., Bucholz, B., Abbas, K. and Foxman, B. (2014) Selected Vaginal Bacteria and Risk of Preterm Birth: An Ecological Perspective. Journal of Infectious Diseases, 209, 1087-1094. https://doi.org/10.1093/infdis/jit632</mixed-citation></ref><ref id="scirp.129986-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Dessi, D., Margarita, V., Cocco, A., Marongiu, A., Fiori, P. and Rappelli, P. (2019) Trichomonas vaginalis and Mycoplasma hominis: New Tales of Two Old Friends. Parasitology, 146, 1150-1155. https://doi.org/10.1017/S0031182018002135</mixed-citation></ref><ref id="scirp.129986-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Bolti, M.A., Alio, H.M., Yakhoub, M.A., NadjiAdjim, N., Akouya, S.D., Allah-Siyangar, N. and Djerabe, N. (2022) Epidemiological Profile of Mycoplasma hominis and Ureaplasma urealyticum Mycoplasmas at the University of N’Djamena Teaching Hospital (CHU-R). British Journal of Healthcare and Medical Research, 9, 88-97. https://doi.org/10.14738/jbemi.92.12119</mixed-citation></ref><ref id="scirp.129986-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Tebeu, P.M., Belinga, E., Sama, J.D., Kenmogne, S.A., Tchente, C. and Sandjong, I. (2020) Epidemiological, Clinical and Therapeutic Aspects of Acute Pelvic Pain in Women at the Yaoundé Gyneco-Obstetric and Pediatric Hospital (HGOPY). The Pan African Medical Journal, 35, Article No. 16. https://doi.org/10.11604/pamj.2020.35.16.14332</mixed-citation></ref><ref id="scirp.129986-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Guindo, I. (2022) Antibiotic Resistance Profile of Mycoplasma hominis and Ureaplasma urealyticum Identified in Women in Bamako, Mali. Revue Malienne d’Infectio-logie et de Microbiologie, 17, 32-37. https://doi.org/10.53597/remim.v17i1.2234</mixed-citation></ref></ref-list></back></article>